biostudies-literatureUnknown28(2)Pandey PImmune checkpoint inhibitors have ushered in a new era of cancer treatment by increasing the likelihood of long-term survival for patients with metastatic disease and by introducing fresh therapeutic indications in cases where the disease is still in its early stages. Immune checkpoint inhibitors that target the proteins cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) or programmed death-1/programmed death ligand-1 have significantly improved overall survival in patients with certain cancers and are expected to help patients achieve complete long-lasting remissions and cures. Some patients who receive immune checkpoint inhibitors, however, either experience therapeutic failure or eventually develop immunotherapy resistance. Such individuals are common, which necessitates a deeper undeMolecules (Basel, Switzerland)862https://www.ebi.ac.uk/biostudies/studies/S-EPMC9863813biostudies-literatureReview to Understand the Crosstalk between Immunotherapy and Tumor Metabolism.PMC9863813Khan FMaqsood RUpadhyay TKPandey PfalseReview to Understand the Crosstalk between Immunotherapy and Tumor Metabolism.Immune checkpoint inhibitors have ushered in a new era of cancer treatment by increasing the likelihood of long-term survival for patients with metastatic disease and by introducing fresh therapeutic indications in cases where the disease is still in its early stages. Immune checkpoint inhibitors that target the proteins cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) or programmed death-1/programmed death ligand-1 have significantly improved overall survival in patients with certain cancers and are expected to help patients achieve complete long-lasting remissions and cures. Some patients who receive immune checkpoint inhibitors, however, either experience therapeutic failure or eventually develop immunotherapy resistance. Such individuals are common, which necessitates a deeper unde2023-01-01T00:00:00Z2023 Jan2025-04-21T23:14:24.064Z2024-11-20T08:04:03.993ZS-EPMC98638133667791910.3390/molecules28020862